Miso Kim

Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

Robert J. Motzer, B. Yа. Alekseev, Sun Young Rha et al. · New England Journal of Medicine · 2021 · 1.7K citations · Full text

Pan-Cancer Immunogenomic Perspective on the Tumor Microenvironment Based on PD-L1 and CD8 T-Cell Infiltration

Chan-Young Ock, Bhumsuk Keam, Sehui Kim et al. · Clinical Cancer Research · 2016 · 285 citations

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Thomas Powles, Piotr Tomczak, Se Hoon Park et al. · The Lancet Oncology · 2022 · 262 citations · Full text

Post-treatment neutrophil-to-lymphocyte ratio at week 6 is prognostic in patients with advanced non-small cell lung cancers treated with anti-PD-1 antibody

Koung Jin Suh, Se Hyun Kim, Yu Jung Kim et al. · Cancer Immunology Immunotherapy · 2017 · 176 citations · Full text

Week 6, Medicine, Immunology +8

PD-L1 expression is associated with epithelial-mesenchymal transition in head and neck squamous cell carcinoma

Chan-Young Ock, Sehui Kim, Bhumsuk Keam et al. · Oncotarget · 2016 · 147 citations · Full text